

Supplement

A hybrid structural approach to analyze ligand binding by the 5-HT4 receptor

Pius S. Padayatti^{1**}, Liwen Wang^{2**}, Sayan Gupta³, Tivadar Orban⁴, Wenyu Sun¹, David Salom¹,
Steve Jordan⁵, Krzysztof Palczewski^{1, 4*}, and Mark R. Chance^{2, 6*}

¹Polgenix Inc., 11000 Cedar Ave., Cleveland, OH 44106, ²Center for Proteomics & Bioinformatics, ³Center for Synchrotron Biosciences, and ⁴Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106. ⁵Department of Molecular Structure, Amgen Inc., Thousand Oaks, CA 91320-1799, ⁶NeoProteomics Inc., 11000 Cedar Ave, Cleveland, OH 44016.

*Correspondence to: Mark R. Chance, Ph.D., Case Center for Proteomics & Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, 10900 Euclid Ave, Cleveland, Ohio 44106-4965, USA. Phone (216) 368-4406, Fax (216) 368-3812, E-mail mark.chance@case.edu; and Krzysztof Palczewski, Ph.D., Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, Ohio 44106-4965, USA; Phone: 216-368-4631; Fax: 216-368-1300; E-mail: kxp65@case.edu.

** contributed equally

Supplementary Table S1. Ligand docking results analyzed with Autodock^a.

Ligand	Binding energy	Inhibitory constant (Ki)	Ki (nM) ^b , [³ H] GR113808
Serotonin	-6.89	204.09 μM	500.73
Cisapride	-5.56	13.05 μM	69.90
GR125487	-10.68	14.8 nM	0.28

^aPredictions from Autodock are in good agreement with experimentally determined binding ranges for these ligands. Values shown are from ligand docking studies done with various ligands for 5-HT₄R along with antagonist GR125487 binding experiment detailed in this study.

^bAverage experimentally determined values of Ki are taken from the PDSP database (<http://pdsp.med.unc.edu/pdsp.php>).

Supplementary Table S2. List of oxidized peptides from 5-HT4R samples with no first order oxidation rates calculated^a


<i>Peptide</i>	Range	Domain	Oxidized AA	Mass shift (Da)
VSSEEGF	8-14	N terminus	E11	-30
ELVQDIWIYGEVF	80-92	ECL1 to TM3	W86 and/or Y88, F92 ^{3.24}	32
IYGEV	87-91	ECL1 to TM3	V91 ^{3.23}	16
CLVRTSLDVLLTT	93-105	TM3	L102 ^{3.31}	16
RTSLDVLL	96-103	TM3	R96 ^{3.28}	-43
ICCQPLV	122-128	ICL2	I122 ^{3.54}	16
TPLRIAL	134-140	TM4	P135 ^{4.39} and I138 ^{4.42}	32
VIPTF	147-151	TM4	V147 ^{4.51} and I148 ^{4.52} /P149 ^{4.53}	32
	147-151	TM4	P 149 ^{4.53}	14
WVIPTF	146-151	TM4	W146 ^{4.50}	16
	146-151	TM4	W146 ^{4.50}	32
FISFL	151-155	TM4	F151 ^{4.55} /I152 ^{4.56}	16
PIMQGWNNIG	156-165	TM4 to ECL2	M158 ^{4.62}	16
MQGWNNIGIIDLIEK	158-172	ECL2	M158 ^{4.62} /I164/W16 1	16

MQGWNNIGIIDLIEK	158-172	ECL2	M158 and W161	48
WNNIG	161-165	ECL2	W161	32
IEKRKFNQNSNSTY	170-183	ECL2	F175	16
VNKPYAIT	188-195	ECL2 to TM5	V188/Y192 ^{5.38}	16
YRIYVT	213-218	TM5	Y213 ^{5.58} /Y216 ^{5.62}	16
YVTAKEHAHQIQL	216-229	ICL3	M228	16
AKEHAHQIQL	219-229	ICL3	H222/H224	-22
AKEHAHQIQL	219-229	ICL3	M228	16
AKEHAHQIQLQ	219-230	ICL3	M228	16
KEHAHQIQL	220-229	ICL3	M228/I226	16
HAHQIQL	222-229	ICL3	M228	16
IQMLQRAGAS	226-235	ICL3	M228	16
IVDPF	280-284	TM6	I280 ^{6.56}	16
NIVDPFID	279-286	TM6 to ECL3	D282 ^{6.58}	-30
CWAPFF	271-276	TM6	W272 ^{6.48}	32
VTNIVDPFI	277-285	TM6	V277 ^{6.53}	16
YTVPGQVW	287-294	TM7	W294 ^{7.35}	32
YTVPGQVWTA	287-296	TM7	W294 ^{7.35} and P290 ^{7.31}	48 (32 and 16)
FLWLG	297-301	TM7	W 299 ^{7.40}	32
INSGLPFL	303-311	TM7	I303 ^{7.44}	16


GLNPFL	306-311	TM7	P309 ^{7.50}	16
FLII	323-326	H8	F323 ^{8.54}	16
AVECGGQW	361-368	C terminus	W368	32
ASMTGGQQMGSATAS KTETSQVAPA	394-417	Tags	M 395 and M 401	32

^a Thirty four unique peptides, apart from the seven peptides shown in Table 1, were detected in ligand-bound and ligand-free 5-HT₄R with modifications, but the rates were not reproducible.


Supplementary Figure S1. Purification and analysis of 5-HT4R. SDS-PAGE in panels A and B. Panel (A) Immunopurified receptor without bound ligand (free) (lane 1) and bound with antagonist GR125487 (lane 2). The final purified ligand-free (lane 1) and bound (lane 2) 5-HT4R preparation used for these experiments is shown in panel (B). The ligand-free samples were prepared by extensive washing during 1D4 affinity chromatography. Soon after elution, both ligand-free and ligand-bound receptors were subjected to PNGase F digestion and then further purified by size exclusion chromatography as shown in (C). The major peak of interest is indicated by an arrow. PNGase F eluted later (smaller peak).



Supplementary Figure S2. Sequence coverage comparison of antagonist-bound and ligand-free samples of 5-HT4R. A) Sequence coverage (95.4%) of GR125487-bound 5-HT4R by LC-MS analysis: Gray lines indicate pepsin digests and purple lines, elastase digests. B) Sequence coverage (94.5%) of ligand-free 5-HT4R achieved by LC-MS analysis.




Supplementary Figure S3. Sequence alignment of model template PDB ID 2Y00 with the 5-HT4R target sequence (388 residues). The alignment was performed with ClustalW. Residue number one for 2Y00 in this figure corresponds to residue number 33 in the PDB and the first 14 residues of 5-HT4R N-terminus are not included in this alignment. Red filled boxes correspond to 100% identity, empty blue outlined boxes with red letters are partial identity and black residues indicate no conservation.




Supplementary Figure S4. Biochemical and functional characterization of 5-HT4R

(A) Concentrations of cAMP formed *in vivo* by cultured insect cells (Sf9). An ELISA-based method was used to quantify cAMP in insect cells cultured on plates. The potent agonist cisapride elevated cAMP levels significantly, whereas incubation of cells with GR125487 (GR) prior to cisapride exposure inhibited cAMP production. (B) Purified 5-HT4R (free) solubilized in DDM was analyzed for ligand binding with the tritiated 5-HT4R antagonist GR113808. Estimated affinity (Kd) for the ligand was about 4.7 nM. The binding analysis was performed with GraphPad software Prism 5.





Supplementary Figure S5. Partial proteolysis of purified 5-HT4R in (A) a ligand-free state (B) an antagonist-bound (GR125487) state. Detergent-solubilized 5-HT4R in DDM/CHS micelles was digested by trypsin followed by digestion with CNBr. Red letters represent 5-HT4R sequence from tryptic peptides identified by MS. Blue lines drawn under the amino acid sequences represent multiple peptides detected that correspond to trypsin sensitive sites. Trypsin digestion sites at R or K residues are indicated by cyan letters. The pattern of digestion in free vs. bound samples is almost identical. Protection against trypsin digestion of one or more R or K residues within TM5 and TM6 helices is indicated by green boxes. Tentative positions of helices TM1 through H8 (brick red), ICL1 through ICL3 (green) and extracellular domains ECL1 through ECL3 (yellow) are indicated by solid lines above the protein sequences. Trypsin cleaved all R and K residues at their C-termini, and CNBr cleaved Met residues at their C-termini.





Supplementary Figure S6. HPLC chromatogram and mass spectrometric identification of oxidized residues from seven peptides for which rates of oxidation were calculated.

Mass spectrometry was used to identify the oxidized residues in the following peptides. (1) Peptide 73-78 with oxidized M74, (2) Peptide 187-195 with oxidized Y192, (3) Peptide 187-195 with oxidized M187, (4) Peptide 187-195 with oxidized Y192, (5) Peptide 187-195 with oxidized M187 and Y192, (6) Peptide 130-140 with oxidized M133, (7) Peptide 227-243 with oxidized M228, (8) Peptide 236-257 with oxidized M251, (9) Peptide 302-308 with oxidized Y302, and (10) Peptide 383-393 with oxidized M392.



Supplementary Figure S6. (contd.)





Supplementary Figure S6. (contd.)





Supplementary Figure S6. (contd.)




Supplementary Figure S6. (contd.)




Supplementary Figure S6. (contd.)




Supplementary Figure S7. Conserved residue Y^{7.43} in the binding pocket of 2RH1, 2VT4 and 5-HT4R (model) bound antagonist. A) Carazolol bound in β 2-AR in close proximity to the antagonist to make a favorable hydrogen bond with Y^{7.43}. B) Cyanopindolol bound to β 1-AR is positioned similar to β 2-AR. C) The same as in the case of β 1-AR, 5-HT4R model with docked GR125487 also positioned favorably at a position to Y^{7.43}.



Supplementary Figure S8. Adding waters from known homologous crystal structures to 5-HT4R model. (A) Overall spatial distribution of waters from crystal structures PDB IDs 2Y00 (pink balls), 2VT4 (dark blue balls) and 2RH1 (golden brown balls) structurally aligned to the 5-HT4R model. Binding of antagonist ligands GR125487 (cyan, docking), carazolol (yellow) and cyanopindolol (silver grey) with respect to the agonist dobutamine (flesh pink) demonstrates highly conserved binding pockets for class A rhodopsin family GPCRs. The distribution of waters is asymmetric within these GPCRs. (B) Overlay of the 5-HT4R model cartoon showing the positions of mass spectrometrically-identified oxidized residues with respect to waters.



Supplementary Figure S9. Lipid bilayer interactions of the 5-HT4R calculated with the OPM server (<http://opm.phar.umich.edu/>). The 5-HT4R model with positions of oxidized residues observed by mass spectrometry is shown with respect to the lipid bilayer. Crystallographic waters were placed into the model as described under Supplementary Figure S5. Residues distributed on the extracellular side most likely are oxidized by the surrounding bulk water because residues within TM helices are oxidized by nearby buried waters located inside the helix bundle. Oxidized residues are colored in rainbow colors starting from the N-terminus to the C-terminus.



Supplementary Figure S10. A comparative view of the binding site interactions showing free against antagonist bound 5-HT4R. (A) In free receptors the Y302^{7.43} and D100^{3.32} are both free to interact with each other. (B) Upon binding of antagonist the Y302^{7.43} is kept in an alternate conformation bound to the ligand so that D100 no longer capable of making a favorable interaction.

